Cocrystal Pharma (COCP) 10% Owner Phillip Frost Buys 75,000 Shares

What Happened Phillip Frost, M.D. (reported as a 10% owner), acquired 75,000 shares of Cocrystal Pharma, Inc. (COCP) on August 3, 2026. The reported weighted-average price was $0.94 per share, for a total purchase value of $70,590. The transaction is reported as a purchase (code P), indicating an open-market or private purchase rather than a sale.

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-05 (timely filing within the usual 2-business-day window).
• Shares acquired: 75,000; reported weighted-average price: $0.94; total value: $70,590.
• Price range: purchases occurred at prices from $0.87 to $0.9499 (footnote F1 — weighted average reported; detailed per-lot prices available on request).
• Ownership vehicle: shares are held by Frost Gamma Investments Trust (footnote F2). Dr. Frost is trustee; Frost Gamma L.P. is the beneficiary; various entity disclaimers note he disclaims beneficial ownership except to extent of pecuniary interest.
• Footnote F3 indicates some reported holdings may include shares issuable upon vesting of restricted stock units.
• Remarks clarify this Form 4 does not include securities owned by OPKO Health, Inc., and Dr. Frost disclaims beneficial ownership of OPKO’s securities except to any pecuniary interest.
• Shares owned after the transaction: not specified in the excerpt provided.

Context This filing reflects a direct purchase by entities tied to Phillip Frost rather than an option exercise or award. For retail investors, purchases by a 10% owner or affiliated trust can be informative, but note the reporting person’s disclaimers about beneficial ownership and the fact that the shares are held in trust structures. The filing is timely and provides a weighted-average price with a disclosed per-lot price range on request (per footnote F1).